Literature DB >> 12951587

Mechanisms of sarcoma development.

Lee J Helman1, Paul Meltzer.   

Abstract

Sarcomas are a rare and diverse group of tumours that are derived from connective tissues, including bone, muscle and cartilage. Although there are instances of hereditary predisposition to sarcomas, the overwhelming majority of such tumours are sporadic. In the past decade, we have gained much insight into the genetic abnormalities that seem to underlie the pathogenesis of these tumours. This information has already led to new classification of many sarcomas, as well as to successful therapies that are targeted at specific genetic abnormalities. It is likely that this approach will lead to continued refinements in classification and treatment of these tumours.

Entities:  

Mesh:

Year:  2003        PMID: 12951587     DOI: 10.1038/nrc1168

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  147 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Chromosomal stability during ex vivo expansion of UCB CD34(+) cells.

Authors:  J Ge; H Cai; W S Tan
Journal:  Cell Prolif       Date:  2011-10-04       Impact factor: 6.831

3.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

Review 4.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 5.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

Review 6.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

7.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

8.  Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.

Authors:  Kojo S J Elenitoba-Johnson; David K Crockett; Jonathan A Schumacher; Stephen D Jenson; Cheryl M Coffin; Alan L Rockwood; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Authors:  Sameer H Issaq; Beverly A Teicher; Anne Monks
Journal:  Cell Cycle       Date:  2014-02-10       Impact factor: 4.534

10.  Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.

Authors:  Antonella Chiechi; Chiara Novello; Giovanna Magagnoli; Emanuel F Petricoin; Jianghong Deng; Maria S Benassi; Piero Picci; Iosif Vaisman; Virginia Espina; Lance A Liotta
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.